Clinical Utility | QF-Pro Glossary

View

Definition

The degree to which a biomarker or diagnostic test improves patient outcomes when used to guide clinical decisions. A test has clinical utility if acting on its results leads to better outcomes than not having the test. This is distinct from analytical validity (does the test measure what it claims?) and clinical validity (does the measurement correlate with a clinical state?). The functional vs expression distinction is ultimately about clinical utility—functional biomarkers demonstrate utility where expression-based tests fail.

Outcome improvement required

Beyond analytical validity

Patient-level evidence

Treatment selection impact

The Three Levels of Biomarker Evidence

Regulatory frameworks distinguish three levels of biomarker validation, each building on the previous:

1. Analytical Validity

Does the test accurately measure what it claims to measure? For FRETLoading...: Does the assay reliably detect energy transfer at expected distances? This is a technical validation question.

2. Clinical Validity

Does the measurement correlate with a clinical condition or outcome? For QF-Pro: Does iFRET-measured PD-1/PD-L1 interaction correlate with survival? This requires patient outcome data.

3. clinical utility

Does using the test to guide treatment improve patient outcomes compared to not using it? This requires prospective interventional studies demonstrating benefit.

Expression-based PD-L1 testing has analytical validity (IHC works) but questionable clinical validity (poor outcome correlation) and uncertain clinical utilityLoading... (many patients denied therapy who would benefit). Functional biomarkersLoading... aim to improve all three levels.

Simplified

Three questions about any biomarker:

1. Does it measure accurately?

Technical question (analytical validity)

2. Does it correlate with outcomes?

Statistical question (clinical validity)

3. Does using it help patients?

The real question (clinical utility)

A test can pass #1 and #2 but still fail #3—which is what matters most.

Why Expression Often Lacks Utility

Expression-based biomarkers frequently demonstrate analytical validity but fail to achieve meaningful clinical utilityLoading.... The fundamental reason: presence does not equal function.

THE PD-L1 TESTING PROBLEM

PD-L1 expression by IHC is FDA-approved for therapy selection, yet:

• Many PD-L1-high patients don't respond to checkpoint inhibitors
• Many PD-L1-low patients do respond to checkpoint inhibitors
• Patients are denied potentially life-saving therapy based on a test with poor predictive accuracy
• The test has analytical validity but marginal clinical utilityLoading...

The functional measurementLoading... approach addresses this directly: by measuring whether PD-1 and PD-L1 are actually interacting, the test captures the mechanism that determines whether blocking that interaction will have therapeutic effect.

In the 2020 melanoma study, iFRET detected functional checkpoint engagement in patients classified as "PD-L1 negative" by IHC—patients who under current guidelines would be deprioritized for immunotherapy but who may in fact have targetable checkpoint activity.

Simplified

The problem with current PD-L1 testing:

• PD-L1-high patients often don't respond
• PD-L1-low patients often do respond
• Patients are denied therapy based on a flawed test

The test "works" technically (IHC staining is accurate), but using it doesn't reliably identify who will benefit from treatment.

Functional testing measures what matters: actual checkpoint engagement, not just protein presence.

Why Clinical Utility Matters

The Utility Gap: Many FDA-approved companion diagnostics have analytical validity (they measure what they claim) but uncertain clinical utility (outcomes may not improve)
PD-L1 Example: IHC-based PD-L1 testing is analytically valid but shows poor correlation with immunotherapy response—functional biomarkers aim to close this gap
Regulatory Evolution: FDA increasingly requires clinical utility evidence, not just analytical performance, for companion diagnostic approval

Connected Terms

Clinical Cutpoint Category Related
Patient Stratification Category Learning Path
ROC Curve Category Related
Melanoma Category Learning Path
NSCLC Category Learning Path
Precision Medicine Category Learning Path
Biomarker Validation Category Cross-ref
Breast Cancer Category Cross-ref